Abbott Cooper PLLC has launched an investigation into potential legal claims on behalf of Kalaris Therapeutics, Inc. stockholders. The investigation focuses on whether the board of directors of Kalaris Therapeutics, formerly known as AlloVir, Inc., breached their fiduciary duties. Stockholders who have continuously held shares since prior to November 7, 2024, are encouraged to contact the firm at no cost or obligation. Abbott Cooper PLLC handles cases on a contingency fee basis, meaning stockholders incur no cost unless a recovery is obtained.
Kalaris Therapeutics, Inc.Investigation into potential fiduciary breaches by the board could lead to legal claims and reputational damage.